Acurx Pharmaceuticals, Inc. (ACXP)
CIK 1736243 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 5.3M shares as of Aug 13, 2026 (10-Q). Share count fell from 23.5M to 1.6M between May 12, 2025 and Aug 11, 2025, a pattern consistent with a reverse split (roughly 1-for-15); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series F Warrants | not tagged | $8 | 2y | — |
| Underwriter Warrants | not tagged | $15 | 5y | — |
| Series E Warrants | not tagged | $18 | 5y | — |
| Pre Funded Warrants | not tagged | $3.029 | — | — |
| Series Warrants | not tagged | $65 | — | — |
| Series B Warrants | not tagged | $65 | — | — |
| Series C Warrants | not tagged | $65.2 | — | — |
| Series D Warrants | not tagged | $65.2 | — | — |
| Series G1 Warrants | not tagged | not tagged | 5y | — |
| Series G2 Warrants | not tagged | not tagged | 5y | — |
| Series G Warrants | not tagged | $8.5 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 2.6M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $2.78 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 7.8M = 5.3M O/S + 2.6M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 13, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 5.3M | Aug 13, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 2.6M | Jun 30, 2026 |
| Fully diluted estimate | 7.8M | +48.9% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $7.8Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 5 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full ACXP workspace